Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C20H22N2O3 |
Molecular Weight | 338.4003 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CO\N=C1\C[C@@H](CO)N(C1)C(=O)C2=CC=C(C=C2)C3=C(C)C=CC=C3
InChI
InChIKey=OLUJSZLBWZWGJT-HGBKYHTQSA-N
InChI=1S/C20H22N2O3/c1-14-5-3-4-6-19(14)15-7-9-16(10-8-15)20(24)22-12-17(21-25-2)11-18(22)13-23/h3-10,18,23H,11-13H2,1-2H3/b21-17-/t18-/m0/s1
Molecular Formula | C20H22N2O3 |
Molecular Weight | 338.4003 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 1 |
Optical Activity | UNSPECIFIED |
Erlosiban (OBE-001 or Nolasiban) is an oral oxytocin receptor antagonist. Erlosiban inhibits myometrium contractions and inflammation elicited by oxytocin. Erlosiban has the potential to decrease contractions and improve uterine blood flow hence enhancing the receptivity of the endometrium to embryo implantation. This may increase the rates of successful implantation, clinical pregnancy, and live-births among patients undergoing ART, or more specifically IVF procedures.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P30559 Gene ID: 5021.0 Gene Symbol: OXTR Target Organism: Homo sapiens (Human) Sources: http://www.obseva.com/pipeline/nolasiban |
Sample Use Guides
In Vivo Use Guide
Sources: http://www.obseva.com/pipeline/nolasiban
Phase III trials: 900 mg nolasiban as a single dose increased ongoing pregnancy and live birth rates
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 17:27:01 GMT 2023
by
admin
on
Fri Dec 15 17:27:01 GMT 2023
|
Record UNII |
3765U8A1EC
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000176871
Created by
admin on Fri Dec 15 17:27:01 GMT 2023 , Edited by admin on Fri Dec 15 17:27:01 GMT 2023
|
PRIMARY | |||
|
10026
Created by
admin on Fri Dec 15 17:27:01 GMT 2023 , Edited by admin on Fri Dec 15 17:27:01 GMT 2023
|
PRIMARY | |||
|
3765U8A1EC
Created by
admin on Fri Dec 15 17:27:01 GMT 2023 , Edited by admin on Fri Dec 15 17:27:01 GMT 2023
|
PRIMARY | |||
|
52947354
Created by
admin on Fri Dec 15 17:27:01 GMT 2023 , Edited by admin on Fri Dec 15 17:27:01 GMT 2023
|
PRIMARY | |||
|
C166647
Created by
admin on Fri Dec 15 17:27:01 GMT 2023 , Edited by admin on Fri Dec 15 17:27:01 GMT 2023
|
PRIMARY | |||
|
1477482-19-1
Created by
admin on Fri Dec 15 17:27:01 GMT 2023 , Edited by admin on Fri Dec 15 17:27:01 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|